T CELL/HISTIOCYTE-RICH LARGE B-CELL LYMPHOMA
Clinical trials for T CELL/HISTIOCYTE-RICH LARGE B-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new T CELL/HISTIOCYTE-RICH LARGE B-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for T CELL/HISTIOCYTE-RICH LARGE B-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo attack on tough lymphoma shows promise
Disease control OngoingThis study tests whether combining the drug acalabrutinib with a cell therapy called liso-cel can shrink or eliminate aggressive B-cell lymphomas that have returned or not responded to prior treatments. About 28 adults with these hard-to-treat cancers will receive the combination…
Matched conditions: T CELL/HISTIOCYTE-RICH LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Patrick C. Johnson, MD • Aim: Disease control
Last updated Jun 16, 2026 12:53 UTC
-
New combo therapy aims to extend remission in elderly lymphoma patients
Disease control OngoingThis study is for people aged 75 or older who have been newly diagnosed with certain aggressive types of B-cell lymphoma. It tests whether adding an oral medication (CC-486, or oral azacitidine) to the standard reduced-dose chemotherapy regimen (R-miniCHOP) can help keep the canc…
Matched conditions: T CELL/HISTIOCYTE-RICH LARGE B-CELL LYMPHOMA
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 15, 2026 19:07 UTC